Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIC HSCT in high-risk inherited metabolic disorders
NCT00383448Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- Sep 2006
- Primary completion
- Sep 2014
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of clofarabine in adrenoleukodystrophy (ALD), metachromatic leukodystrophy (MLD), globoid cell leukodystrophy (GLD), GM1 gangliosidosis (GM1), Tay-Sachs disease (TSD), sponsored by Masonic Cancer Center. Started Sep 2006; status: completed.
02
Drugs
clofarabine
03
Conditions
adrenoleukodystrophy (ALD)metachromatic leukodystrophy (MLD)globoid cell leukodystrophy (GLD)GM1 gangliosidosis (GM1)Tay-Sachs disease (TSD)
Beyond the preview
Go deeper on NCT00383448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00383448.